Innovative Antibody Treatment from Human Breast Milk Shows Promise Against Influenza

In a groundbreaking study published in Science Advances, Lactiga US, Inc., a biotechnology company innovating in human milk-derived antibody treatments, has revealed exciting findings that could revolutionize the way we approach respiratory infections. Collaborating with McMaster University, the research underscores the potential of a nasal antibody formulation, LCTG-001, in offering protection against influenza, marking a significant milestone for patients with compromised immune systems.

The Research Findings

The preclinical study highlighted LCTG-001's effectiveness in protecting antibody-deficient mice from influenza infections. Notably, all five treated mice survived, while only two out of five in the control cohort did. This extraordinary outcome paves the way for developing essential therapies for individuals suffering from common variable immunodeficiency (CVID), who continue to battle respiratory infections despite existing treatment options.

Mice that received the LCTG-001 treatment exhibited far less weight loss and lung damage related to influenza. While the treated subjects experienced a notable peak weight loss of about 7.7%, their counterparts in the control group faced a severe peak loss of approximately 22.8%. Furthermore, the treatment significantly reduced lung inflammation and preserved lung tissue, even when viral loads were comparable between both groups.

This impressive data suggests that the secretory immunoglobulin A (sIgA) in LCTG-001 plays a critical role in protecting against infections. It helps to mitigate tissue damage associated with the virus, indicating a multifaceted approach to viral defense.

Transforming Science into Therapeutics

Rikin Mehta, Co-Founder and CEO of Lactiga, remarked, "Mothers have always known breast milk is liquid gold, and at Lactiga we're using science to prove why. Our research demonstrates that one of its natural protective components, secretory IgA, can neutralize multiple respiratory viruses and protect against influenza in animal studies. We’re now translating our science into a new class of potentially lifesaving therapeutics for patients."

The study also illustrated LCTG-001's antiviral activity against several viruses, including respiratory syncytial virus (RSV), adenovirus, and highly pathogenic avian influenza A (H5N1). The breadth of LCTG-001’s protective capabilities offers a glimpse into a promising future, where polyclonal secretory IgA can be utilized as a broad-acting antibody treatment.

A Step Towards Clinical Development

Despite the effectiveness of conventional immunoglobulin therapies for CVID patients, they fail to restore the protective secretory IgA antibodies essential for safeguarding the nasal passages. LCTG-001 is on a mission to fill this gap, targeting nasal antibody replacement.

The treatment has already received Orphan Drug and Rare Pediatric Disease designations from the U.S. FDA for CVID, expediting its journey towards first-in-human clinical trials. In these studies, Lactiga aims to explore this novel approach toward antibody replacement specifically designed for individuals vulnerable to severe and recurrent infections.

About Lactiga

Lactiga US, Inc. is at the forefront of biotechnology, focusing on the development of mucosal antibody treatments sourced from human breast milk. By innovating with polyclonal secretory immunoglobulin A (sIgA), Lactiga seeks to address chronic diseases and immune irregularities within susceptible patient populations. Their flagship product, LCTG-001, is set to impact patients enduring recurrent respiratory infections, while the company has broader ambitions, including a range of sIgA treatments for conditions like inflammatory bowel disease.

In summary, the findings from Lactiga provide a compelling case for the incorporation of natural compounds found in human milk into modern medicine, revealing a pathway towards innovative treatments for conditions such as CVID, while simultaneously offering a broader defense against various respiratory viruses. For more information about Lactiga and their pioneering work, visit www.lactiga.com.